REPROBESITY

Search for new therapeutic agents against complicated obesity by reprofiling existing drugs

Coordinatore	FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD    more  Organization address address: AVENIDA JORGE LUIS BORGES 15 city: MALAGA postcode: 29010 contact info Titolo: Dr. Nome: Fernando Cognome: Rodriguez De Fonseca Email: send email Telefono: 34951030446 Fax: 34951239191
Nazionalità Coordinatore	Spain [ES]
Sito del progetto	http://www.reprobesity.eu/
Totale costo	6˙946˙279 €
EC contributo	5˙399˙412 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-B
Funding Scheme	CP-TP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-12-01   -   2012-05-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	FUNDACION PUBLICA ANDALUZA PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD  Organization address address: AVENIDA JORGE LUIS BORGES 15 city: MALAGA postcode: 29010 contact info Titolo: Dr. Nome: Fernando Cognome: Rodriguez De Fonseca Email: send email Telefono: 34951030446 Fax: 34951239191	ES (MALAGA)	coordinator	0.00
2	ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA  Organization address address: Via Zamboni 33 city: BOLOGNA postcode: 40126 contact info Titolo: Dr. Nome: Alessandra Cognome: Malavolta Email: send email Telefono: +39 051 20 99338 Fax: +39 051 2099379	IT (BOLOGNA)	participant	0.00
3	INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)  Organization address address: 101 Rue de Tolbiac city: PARIS postcode: 75654 contact info Titolo: Dr. Nome: Giovanni Cognome: Marsicano Email: send email Telefono: 33557573657 Fax: 33557573669	FR (PARIS)	participant	0.00
4	JOHANNES GUTENBERG UNIVERSITAET MAINZ  Organization address address: SAARSTRASSE 21 city: MAINZ postcode: 55099 contact info Titolo: Prof. Nome: Beat Cognome: Lutz Email: send email Telefono: 4961310000000 Fax: 4961310000000	DE (MAINZ)	participant	0.00
5	UNIVERSIDADE DE SANTIAGO DE COMPOSTELA  Organization address address: "PAZO DE SAN XEROME, PRAZA DO OBRADOIRO S/N" city: SANTIAGO DE COMPOSTELA postcode: 15782 contact info Titolo: Dr. Nome: Fernando Cognome: Sedano Arnaez Email: send email Telefono: +34 981 547050 Fax: +34 981 528019	ES (SANTIAGO DE COMPOSTELA)	participant	0.00
6	UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ  Organization address address: Langenbeckstrasse 1 city: Mainz postcode: 55131 contact info Titolo: Dr. Nome: Uta Cognome: Veith Email: send email Telefono: +49 613 117 9717 Fax: +49 613 117 9669	DE (Mainz)	participant	0.00
7	VIVIA BIOTECH S.L.  Organization address address: C SANTIAGO GRISOLIA 2 OFICINA 205 city: TRES CANTOS MADRID postcode: 28760 contact info Titolo: Ms. Nome: Olivia Cognome: De La Lama Noriega Email: send email Telefono: +34 679 324769 Fax: +34 951291447	ES (TRES CANTOS MADRID)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Obesity is one of the most serious and fast-growing health problem in the European Union, and a leading cause of diabetes. The main barrier for approval of an anti-obesity drug is the safety requirements. We propose to overcome this barrier by discovering phenotypes and biomarkers that identify subsets of patients with safe and efficacious responses to drugs, and by identifying new indications of existing drugs with proven safety profiles. To be approved, anti-obesity drugs need to show a decrease in abdominal fat. We focus on approaches targeting directly abdominal fat cells. In the last years only the cannabinoid CB1 receptor antagonist Rimonabant has been approved as a therapeutic agent to combat complicated obesity. Research performed with this drug has clearly revealed a role for the endogenous cannabinoid system in controlling energy homeostasis. However, its utility is limited to a restricted set of patients. A new phenotype and/or biomarker may identify responsive patients with good safety profiles. This proposal aims to discover novel or improved treatments in the shortest possible timeframe through three synergistic Specific Aims: 1) Clinical phenotyping of obese patients to identify those that would benefit from existing therapies such as Rimonabant. 2) Discover biomarkers for subsets of obese patients that may correlate with therapeutical outcomes. These biomarkers will be discovered by a novel approach called Combinatorial Cytomic Biomarkers developed by OrphaMed, applied to cells from two physiologically interlinked sources: blood and abdominal-fat samples, extracted from the above phenotyped patients. 3) Identify new indications of existing drugs, alone or in combination, with potential anti-obesity efficacy by lowering the fat content and the glucose uptake of abdominal fat cells, which would be expected to improve carbohydrate/lipid metabolism and lower body weight, extracted from the above phenotyped patients. This will be accomplished by screening approximately 2.000 known drugs against these fat cells using the novel technology platform “ExviTech” from OrphaMed. Candidates would be evaluated in animal models of obesity.'